Salud financiera de hoja de balance de Nurix Therapeutics
Salud financiera controles de criterios 6/6
Nurix Therapeutics tiene un patrimonio de los accionistas total de $168.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $312.7M y $143.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$243.99m |
| Patrimonio | US$168.75m |
| Total pasivo | US$143.93m |
| Activos totales | US$312.67m |
Actualizaciones recientes sobre salud financiera
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Recent updates
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Apr 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($251.0M) de NRIX superan a sus pasivos a corto plazo ($87.6M).
Pasivo a largo plazo: Los activos a corto plazo de NRIX ($251.0M) superan a sus pasivos a largo plazo ($56.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: NRIX está libre de deudas.
Reducción de la deuda: NRIX no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: NRIX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: NRIX dispone de suficiente cash runway para 1.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 43.8% cada año.